Shots:

• The P-III HIMALAYA study Imfinzi monothx. and the STRIDE regimen (single priming dose of tremelimumab 300mg + Imfinzi 1500mg followed by Imfinzi q4w vs sorafenib in ~1-324 patients with unresectable- advanced HCC who had not been treated with prior systemic therapy and were not eligible for locoregional therapy
• The combination regimen demonstrated a favorable safety profile & the addition of tremelimumab to Imfinzi did not increase severe hepatic toxicity. Imfinzi monothx. demonstrated a non-inferior OS to sorafenib
• Imfinzi and tremelimumab received the US FDA’s ODD for the treatment of HCC in 2020 whereas Tremelimumab was granted ODD in the EU in HCC in 2020

  Ref: AstraZeneca | Image: Twitter